No Data
No Data
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,245
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242